Confronting Pancreatic Cancer

Pancreas Cancer News and Archives

For educational purposes only; not to be relied upon. Please read Pancreatica Disclaimer

SuperGen Submits First Module of Orathecin's(TM) 'Rolling' New Drug Application as an Oral Treatment for Pancreatic Cancer

December 30, 2002
Dublin, California

Submission anticipated to be completed by end of 2003 first-quarter

SuperGen Inc. announced today that it has begun submission of a New Drug Application (NDA) for its anticancer compound Orathecin(TM), an oral chemotherapy compound in the camptothecin class, for the treatment of pancreatic cancer patients who are refractory (resistant) to available therapies. The submission will occur on a 'rolling' basis and is expected to be completed by the end of the first-quarter of 2003. The first module submitted contained the chemistry, manufacturing and controls (CMC) section.

The NDA submission will contain data on over 2,700 patients treated under Orathecin study protocols and will be based on the company's Phase III clinical program, the largest randomized pancreatic cancer program ever initiated worldwide. The submission will also be supported by data from a Phase II clinical study of Orathecin in refractory pancreatic cancer. The Phase II data were presented at the 2000 Annual Meeting of the American Society of Clinical Oncology (ASCO) and were reviewed by an independent third- party expert radiology review panel.

"The beginning of this submission is extremely gratifying for myself and all of our team members who have dedicated themselves to this program for more than five years," said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. "More importantly, in a disease with a fatality rate of 98 percent, there is a screaming need for new therapies and we are now one step closer to offering real hope to the more than 30,000 Americans who suffer from one of the most lethal of all cancers.

"During the course of this submission, we will continue to engage in regular meetings with the FDA to ensure that the process is thorough and on schedule," added Dr. Rubinfeld. "Assuming there are no unforeseen delays, we anticipate presenting the data from our Phase III Orathecin program at the Annual Meeting of ASCO next May."

Last month, the company was granted a 'fast-track' designation for Orathecin. Fast-track designation means that the FDA will facilitate and expedite the development and review of the application for the approval of a new drug, if it is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to address an unmet medical need.

Pancreatic cancer is associated with high patient mortality causing more than 75,000 deaths annually worldwide. It is the fourth-leading cause of death by cancer in the United States with an average one-year survival rate of less than 5 percent.

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer. The company's website can be reached at www.supergen.com.

This press release contains 'forward-looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such forward-looking statements include statements regarding our expectations about Orathecin(TM). The success of such a product could differ materially from those projected in the forward-looking statements as a result of known and unknown risk factors and uncertainties. Such factors may include, but are not limited to: risks and uncertainties related to how quickly data can be analyzed to submit an NDA with the FDA, the results of the studies, how lengthy the FDA review process will take, if the application will be accepted, filed, and approved or if Orathecin will ever reach the market. Reference is made to the discussion of risk factors detailed in the Company's filings with the Securities and Exchange Commission, including the report on Form 10-K for the year ending 2001 and the report on Form 10-Q for the quarter ending September 30, 2002.

Press Release
SOURCE: SuperGen Inc.

Home | In The News | Links | FAQ | Donations
Clinical Trials Database | Research Resources | About Us

webmaster

©2000-2008 Pancreatica.org - All Rights Reserved
www.pancreatica.org

	Pancreas Cancer News and Archives
		For educational purposes only; not to be relied upon. Please read Pancreatica Disclaimer
	SuperGen Submits First Module of Orathecin's(TM) 'Rolling' New Drug Application as an Oral Treatment for Pancreatic Cancer December 30, 2002 Dublin, California Submission anticipated to be completed by end of 2003 first-quarter SuperGen Inc. announced today that it has begun submission of a New Drug Application (NDA) for its anticancer compound Orathecin(TM), an oral chemotherapy compound in the camptothecin class, for the treatment of pancreatic cancer patients who are refractory (resistant) to available therapies. The submission will occur on a 'rolling' basis and is expected to be completed by the end of the first-quarter of 2003. The first module submitted contained the chemistry, manufacturing and controls (CMC) section. The NDA submission will contain data on over 2,700 patients treated under Orathecin study protocols and will be based on the company's Phase III clinical program, the largest randomized pancreatic cancer program ever initiated worldwide. The submission will also be supported by data from a Phase II clinical study of Orathecin in refractory pancreatic cancer. The Phase II data were presented at the 2000 Annual Meeting of the American Society of Clinical Oncology (ASCO) and were reviewed by an independent third- party expert radiology review panel. "The beginning of this submission is extremely gratifying for myself and all of our team members who have dedicated themselves to this program for more than five years," said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. "More importantly, in a disease with a fatality rate of 98 percent, there is a screaming need for new therapies and we are now one step closer to offering real hope to the more than 30,000 Americans who suffer from one of the most lethal of all cancers. "During the course of this submission, we will continue to engage in regular meetings with the FDA to ensure that the process is thorough and on schedule," added Dr. Rubinfeld. "Assuming there are no unforeseen delays, we anticipate presenting the data from our Phase III Orathecin program at the Annual Meeting of ASCO next May." Last month, the company was granted a 'fast-track' designation for Orathecin. Fast-track designation means that the FDA will facilitate and expedite the development and review of the application for the approval of a new drug, if it is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to address an unmet medical need. Pancreatic cancer is associated with high patient mortality causing more than 75,000 deaths annually worldwide. It is the fourth-leading cause of death by cancer in the United States with an average one-year survival rate of less than 5 percent. Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer. The company's website can be reached at www.supergen.com. This press release contains 'forward-looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such forward-looking statements include statements regarding our expectations about Orathecin(TM). The success of such a product could differ materially from those projected in the forward-looking statements as a result of known and unknown risk factors and uncertainties. Such factors may include, but are not limited to: risks and uncertainties related to how quickly data can be analyzed to submit an NDA with the FDA, the results of the studies, how lengthy the FDA review process will take, if the application will be accepted, filed, and approved or if Orathecin will ever reach the market. Reference is made to the discussion of risk factors detailed in the Company's filings with the Securities and Exchange Commission, including the report on Form 10-K for the year ending 2001 and the report on Form 10-Q for the quarter ending September 30, 2002. Press Release SOURCE: SuperGen Inc.

	Home \| In The News \| Links \| FAQ \| Donations Clinical Trials Database \| Research Resources \| About Us

	webmaster

	©2000-2008 Pancreatica.org - All Rights Reserved www.pancreatica.org